Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
about
Icotinib is an active treatment of non-small-cell lung cancer: a retrospective studyNetwork meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutationsThird-line systemic treatment for non-small cell lung cancerThe Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-AnalysisChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerThe Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-AnalysisThe Role of End-of-Life Issues in the Design and Reporting of Cancer Clinical Trials: A Structured Literature ReviewIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughChina Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized TrialsRole of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patientsEmerging treatments and combinations in the management of NSCLC: clinical potential of nintedanibSecond-Line Therapy for Advanced NSCLCNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateOverall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer.Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials.Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerPercutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non-Small Cell Lung CancerPruritus in patients treated with targeted cancer therapies: systematic review and meta-analysisPooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLCImpact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib.Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis.Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome.Predictive efficacy of low burden EGFR mutation detected by next-generation sequencing on response to EGFR tyrosine kinase inhibitors in non-small-cell lung carcinoma[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients
P2860
Q21132047-B95EE529-49DD-4D2E-8959-0B93289F4B82Q21132357-58C7E967-20C3-40F6-A1A5-EC8F7867D28FQ24194090-2A5096CA-D808-4799-84E3-4B7B31221F44Q26772052-53003569-D71C-4929-BE88-96BE143D3BDEQ26775603-96018A83-C707-45FB-91AC-19D3E1206CE3Q26775677-8C6B0756-9F9C-41E3-AF8F-3A70318F83F9Q26784298-5DAF51A4-2912-47FA-8907-8F979023D07BQ26786142-2B4A7102-5E63-4198-B1D9-5D5AC39284B1Q26795613-D08B58FA-D856-4CED-942D-75F0EE47FEE7Q26798882-E7FB07BB-9FB7-420A-A104-0E2C292D2B9DQ26799467-D98F3C5E-B5A1-44E6-861B-4CEB1046BB6CQ26800148-B3900CBE-370F-4BA3-B6D5-5ADB628621CAQ26825636-8627B807-3FBC-4859-ADF0-61C5CE8DEE2AQ26866485-35CBFB1D-FA0E-479D-80CB-D810ADF8641AQ26995204-71257F1A-41AF-4446-91FA-455D32BA0928Q27002398-D605E0D0-3AF8-49F1-8822-3B5DAF7512B1Q27003440-D960F082-757A-46E5-B730-B02278EF9148Q27022535-888A7D50-D32A-4AFD-AE70-08F1FFD5262EQ28068643-B59ED263-0807-47C9-8F39-EE412DF983E7Q30248499-FE23AE47-06A8-48F9-8DE9-939EA4F8AB79Q30356434-07160DA3-E791-4079-818D-25BF1F481C97Q30588681-766159D3-B640-4553-88BC-75A38C9C032FQ33407582-B72D94A2-006F-46A3-A224-BADEF292380AQ33416457-991DE765-E1FD-465F-AD7F-DC2DA71D5362Q33710146-3AA7040F-83E3-42AE-960B-251CE3DE6392Q33779741-5AFEF058-1AF7-4D8E-9614-7ABF654E9B3FQ33873095-3050679D-DAAB-4AB7-B642-75105B4A27CCQ33912220-1D7CCEBB-BD60-42F6-8551-07AE4A9ADEF8Q34272887-D4B271D8-1881-4930-B926-2553A3495C32Q34311186-0E20B41A-85F3-44DA-A95C-EC12468E5050Q34339890-6B4DC350-E7EE-4D9D-B6C5-7C39C767ACF5Q34353920-9F03FCC1-9C1C-46F7-AE34-B5BB905B3E2DQ34427439-8BED83DC-F3F6-4B59-874F-147CFBE8DD8BQ34430535-B3DF9F54-B97A-4D2D-A786-A20181CD373BQ34452186-92916068-773D-45B3-9EA5-4D0A759A7C48Q34637855-DD85FDCC-AA3D-4F28-8B2F-52D81AB83E23Q34663877-A3AF5300-8E9B-4F8D-8C69-4D46FC8EDBBBQ34906960-9C581F9A-EFFC-4B8D-9CC1-9AB25311881BQ35077521-A2E84C3E-224A-4044-A361-4AF3F43C27F3Q35088202-8CFE4382-0D2C-44A5-B7EC-E782E61511A2
P2860
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@en
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@nl
type
label
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@en
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@nl
prefLabel
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@en
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@nl
P2093
P1433
P1476
Efficacy and safety of erlotin ...... re, open-label, phase 3 study.
@en
P2093
Alexandru Calin Grigorescu
Barbara Klughammer
Carina Hillenbach
Emilio Esteban Gonzalez
Hrefna Kristin Johannsdottir
Lilia Stelmakh
Saulius Cicenas
Skaidrius Miliauskas
Tudor Ciuleanu
P304
P356
10.1016/S1470-2045(11)70385-0
P577
2012-01-24T00:00:00Z